Idsk -- The thrombopoietin mimetic romiplostim produced a higher rate of platelet response, a lower incidence of treatment failure, less need for splenectomy, and less bleeding than did a variety of standard-of-care therapies in patients with immune thrombocytopenia, according to a report in the Nov. 11 issue of the New England Journal of Medicine.
